Search results for " Risk factor"

showing 10 items of 612 documents

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

2013

International audience; Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear, but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities. We report on a cohort of MEN1 patients from the Groupe d'étude des Tumeurs Endocrines. Patients with a…

OncologyMaleendocrine system diseasesProto-Oncogene Proteins c-jun[SDV]Life Sciences [q-bio]Diseasemedicine.disease_causeMESH: Protein Structure Tertiary0302 clinical medicineRisk FactorsMESH: Risk FactorsMESH : FemaleGenetics (clinical)MutationGeneral MedicineMESH: Follow-Up StudiesMESH : Risk Factors3. Good health030220 oncology & carcinogenesisCohortMESH : Proto-Oncogene ProteinsFemaleMESH : MutationMESH : Protein Structure TertiaryMESH : Proto-Oncogene Proteins c-junMESH : Multiple Endocrine Neoplasia Type 1Cohort studymedicine.medical_specialtyendocrine systemMESH: MutationGenetic counselingMESH : MaleMESH: Multiple Endocrine Neoplasia Type 1030209 endocrinology & metabolismBiology03 medical and health sciencesInternal medicineProto-Oncogene ProteinsGeneticsmedicineMultiple Endocrine Neoplasia Type 1HumansMEN1FamilyMolecular BiologyMESH: FamilyMESH: HumansMESH: Proto-Oncogene Proteins c-jun[ SDV ] Life Sciences [q-bio]Proportional hazards modelMESH : HumansCancerMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleProtein Structure TertiaryMESH: Proto-Oncogene ProteinsMutationCancer researchMESH : FamilyMESH: FemaleFollow-Up Studies
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant.

2019

BACKGROUND One of the most controversial problems for liver transplantation in patients affected by hepatocellular carcinoma (HCC) remains the lack of an oncologic staging system to predict cancer recurrence after liver transplantation (LT). We analyzed allelic imbalance (AI) in 19 microsatellites, and assessed the post-LT HCC recurrence risk. MATERIAL AND METHODS Seventy-one patients were included; 18 had tumor recurrence within 5 years post-transplant. Molecular analysis was done in the primary HCC and peripheral blood samples: a total of 19 microsatellites was used to assess AI. Specific AI was evaluated when outside of range value between 0.66 and 1.5. Based on data in the literature, w…

OncologyMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationAllelic ImbalanceCancer recurrenceRecurrence risk03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientAgedRetrospective StudiesTransplantationOriginal Paperbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPeripheral bloodMolecular analysisLiver TransplantationTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinomaAllelic Imbalance030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence LocalbusinessAllelic Imbalance Carcinoma Hepatocellular Liver Transplantation Treatment Outcome Aged Carcinoma Hepatocellular Female Humans Liver Neoplasms Male Middle Aged Neoplasm Recurrence Local Prognosis Retrospective Studies Risk Factors Treatment Outcome Allelic Imbalance Liver TransplantationAnnals of transplantation
researchProduct

Metabolic disorders across hepatocellular carcinoma in Italy

2018

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, pati…

OncologyMaleobesityDatabases FactualHepatocellular carcinoma0302 clinical medicineRisk FactorsProspective cohort studydiabetesMetabolic disorderLiver NeoplasmsDiabeteshepatocellular carcinomaMiddle AgedMetabolic syndromePortal vein thrombosisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADiabetes; Hepatocellular carcinoma; Metabolic syndrome; Obesitymetabolic syndrome03 medical and health sciencesDatabasesMetabolic DiseasesInternal medicinemedicineDiabetes MellitusHumansObesityFactualAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseaseSurvival AnalysisBCLC Stagediabetes; hepatocellular carcinoma; metabolic syndrome; obesity; Aged; Carcinoma Hepatocellular; Databases Factual; Diabetes Mellitus; Female; Humans; Italy; Liver Neoplasms; Male; Metabolic Diseases; Middle Aged; Multivariate Analysis; Neoplasm Staging; Obesity; Retrospective Studies; Risk Factors; Survival AnalysisdiabeteMultivariate AnalysisLiver functionMetabolic syndromebusiness
researchProduct

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

2013

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospe…

OncologyNon-Clinical Medicinemedicine.medical_treatmentCancer Treatmentlcsh:MedicineEstrogen receptorBioinformaticsMetastasisSurveys and QuestionnairesPathologylcsh:ScienceMultidisciplinaryMolecular pathologyCancer Risk FactorsHormonal TherapyObstetrics and GynecologyEndocrine TherapyMiddle AgedOncologyReceptors EstrogenCohortMedicineFemaleRisk assessmentMolecular PathologyResearch ArticleAdultmedicine.medical_specialtyAntineoplastic Agents HormonalGenetic Causes of CancerClinical Decision-MakingBreast NeoplasmsRisk AssessmentBreast cancerDiagnostic MedicineInternal medicineBreast CancermedicineHumansAgedRetrospective StudiesChemotherapyHealth Care Policybusiness.industryGene Expression Profilinglcsh:RHealth Risk AnalysisRetrospective cohort studyChemotherapy and Drug Treatmentmedicine.diseaselcsh:QbusinessGeneral PathologyPLoS ONE
researchProduct

Sorafenib: from literature to clinical practice

2013

Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further …

OncologyTime Factorsadverse eventPharmacologySystemic therapylaw.inventionTranslational Research Biomedicalobservational studieAntineoplastic AgentRandomized controlled trialRisk FactorslawMolecular Targeted TherapyHCCTranslational Medical Researchadverse events; clinical practice; observational studies; randomized clinical trials; sorafenib; Animals; Antineoplastic Agents; Carcinoma Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Molecular Targeted Therapy; Translational Medical ResearchRandomized Controlled Trials as TopicEvidence-Based MedicineLiver NeoplasmsHematologyclinical practiceTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaHumanmedicine.drugNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorProtein Kinase InhibitorAntineoplastic AgentsInternal medicinemedicineAnimalsHumansAdverse effectProtein Kinase InhibitorsneoplasmsNeoplasm StagingAnimalbusiness.industryPhenylurea CompoundsRisk FactorEvidence-based medicinerandomized clinical trialmedicine.diseasedigestive system diseasessorafenibObservational studyLiver functionbusiness
researchProduct

Relations of Metabolically Healthy and Unhealthy Obesity to Digital Vascular Function in Three Community‐Based Cohorts: A Meta‐Analysis

2017

Background Microvascular dysfunction is a marker of early vascular disease that predicts cardiovascular events. Whether metabolically healthy obese individuals have impaired microvascular function remains unclear. The aim of this study was to evaluate the relation of obesity phenotypes stratified by metabolic status to microvascular function. Methods and Results We meta‐analyzed aggregate data from 3 large cohorts (Brazilian Longitudinal Study of Adult Health, the Framingham Heart Study, and the Gutenberg Heart Study; n=16 830 participants, age range 19–90, 51.3% men). Regression slopes between cardiovascular risk factors and microvascular function, measured by peripheral arterial tonometr…

Oncologycardiovascular risk factorsMaleEpidemiology030204 cardiovascular system & hematologyOverweightCohort Studies0302 clinical medicineendothelial functionRisk FactorsGermanyVascular Disease030212 general & internal medicine2. Zero hungerSystematic Review and Meta‐AnalysisMiddle Aged3. Good healthMeta-analysisPulsatile FlowEndothelium/Vascular Type/Nitric OxideFemalemedicine.symptomCardiology and Cardiovascular MedicineBrazilCohort studyAdultmedicine.medical_specialtyManometrybody mass indexmetabolic syndromeFingers03 medical and health sciencesInternal medicinemedicineHumansObesityAgedObesity Metabolically BenignVascular diseasebusiness.industryCase-control studyOverweightmedicine.diseaseObesityUnited StatesEndocrinologyCase-Control StudiesMicrovesselsEndothelium VascularMetabolic syndromebusinessBody mass indexJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct

Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder

2006

<i>Objective:</i> The distribution of potential environmental risk factors among patients affected by superficial transitional cell carcinoma of the bladder (TCCB) has been analyzed. <i>Methods:</i> Patients affected by superficial TCCB underwent TUR and early intravesical chemotherapy. Detailed data about age, sex, residence, employment, active and passive cigarette smoking, water resource and hair dye use were centralized. Analysis has been conducted on 474 patients affected by Ta-T1 G1-2 TCCB at medium risk for recurrence. Patients with primary single Ta G1-2, Tis or T1G3 tumors were excluded from the present analysis. <i>Results:</i> Over 80% of the p…

Oncologymedicine.medical_specialtyBladder cancerbusiness.industryUrologyBladder cancer Bladder cancer environmental risk factors Ta-T1 transitional cell carcinoma SmokingUrologymedicine.diseaseTransitional cell carcinomaEnvironmental riskPreliminary reportInternal medicinemedicinebusiness
researchProduct

Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis

2017

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post–endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be inclu…

Oncologymedicine.medical_specialtyColorectal cancerBiopsyTumor buddingAdenocarcinomaRisk AssessmentPathology and Forensic MedicineColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor buddingColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor budding; Adenocarcinoma; Biopsy; Colorectal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Cell MovementLymph node metastasi03 medical and health sciences0302 clinical medicineTumor buddingPredictive Value of TestsRisk FactorsCell MovementTumor budding.Internal medicineBiopsymedicineOdds RatioHumansMeta-analysiNeoplasm InvasivenessRisk factorNeoplasm StagingLymph node metastasismedicine.diagnostic_testbusiness.industryCancerOdds ratiomedicine.diseaseColorectal cancerSurgeryMeta-analysis030220 oncology & carcinogenesisPredictive value of testsLymphatic MetastasisAdenocarcinoma030211 gastroenterology & hepatologyLymph NodesbusinessColorectal NeoplasmsSprouting
researchProduct